Key facts
- This page summarizes BioXcel LLC's Form 4 filing for BioXcel Therapeutics, Inc. (BTAI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 29 Jun 2021, 17:22.
BioXcel LLC - 25 Jun 2021 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- BTAI
- Reported as of
- 25 Jun 2021
- Net transaction value
- -$14,589,493
- Reporting owner signature
- /s/ Krishnan Nandabalan, President
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
BioXcel LLC filed Form 4 for BioXcel Therapeutics, Inc. (BTAI) on 29 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$14,589,493.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BTAI
transaction
Common Stock
Sale
- Transaction value
- $14,589,493
- Shares
- -473,250
- Change %
- -5.2%
- Price
- $30.83
- Shares after
- 8,546,750
- Date
- 25 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
On June 25, 2021, the Reporting Person sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70 per share . The reported sale price reflects the price at which the Reporting Person sold shares to the underwriters after underwriting discounts and commissions.